What is Blaze Bioscience?
Blaze Bioscience operates at the intersection of advanced molecular imaging and surgical oncology. The company is primarily recognized for its proprietary Tumor Paint technology, a molecular imaging platform designed to provide real-time visualization of cancer cells during surgical procedures. By integrating this technology with the CANVAS imaging system, Blaze Bioscience aims to enhance the precision of tumor resection, thereby improving surgical outcomes for patients, with a specific focus on pediatric brain cancer. This technological stack positions the firm as a critical player in the precision medicine market, offering healthcare institutions a sophisticated toolset to increase the sensitivity and reliability of cancer care protocols.
How much funding has Blaze Bioscience raised?
Blaze Bioscience has raised a total of $17M across 7 funding rounds:
Debt
$725K
Series A
$5M
Series B
$9M
Debt
$991K
Debt
$554K
Debt
$350K
Debt
$421K
Debt (2011): $725K, investors not publicly disclosed
Series A (2012): $5M, investors not publicly disclosed
Series B (2013): $9M, investors not publicly disclosed
Debt (2015): $991K, investors not publicly disclosed
Debt (2017): $554K, investors not publicly disclosed
Debt (2020): $350K with participation from PPP
Debt (2021): $421K led by PPP
Key Investors in Blaze Bioscience
PPP
Public-Private Partnership
Undisclosed Investors
Undisclosed Investors
What's next for Blaze Bioscience?
With the infusion of this recent capital, Blaze Bioscience is well-positioned to accelerate its clinical pipeline and scale the deployment of its imaging systems across major oncology centers. The strategic focus will likely shift toward expanding the regulatory footprint of its core technologies and deepening its market penetration in the surgical oncology sector. As the company transitions into a more mature operational phase, the emphasis will remain on validating the clinical efficacy of its imaging solutions while optimizing the commercialization strategy to ensure broader accessibility for healthcare providers globally. Future growth will be contingent upon successful clinical milestones and the continued adoption of its imaging platforms in standard-of-care surgical workflows.
See full Blaze Bioscience company page
